Table 3.
Criterion | Step 1 | Step 2 | Step 3 | Step 4 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Age, Sex, ICV | Right Brodmann’s area 9 | Group | Interaction | |||||||||
β | Δr2 | f2 | β | Δr2 | f2 | β | Δr2 | f2 | β | Δr2 | f2 | |
WISC Verbal comp | -- | 0.243* | 0.32 | 0.40 | 0.149* | 0.25 | 0.59 | 0.282*** | 0.87 | 0.05 | 0.002 | 0.01 |
WCST_PE | -- | 0.106 | 0.12 | 0.21 | 0.039 | 0.05 | 0.41 | 0.145* | 0.20 | −0.14 | 0.016 | 0.02 |
WCST_CLR | -- | 0.196 | 0.24 | 0.29 | 0.076 | 0.10 | 0.51 | 0.220*** | 0.43 | −0.02 | 0.000 | 0.00 |
CPT_AX | -- | 0.234* | 0.31 | 0.15 | 0.020 | 0.03 | 0.72 | 0.438*** | 1.40 | −0.04 | 0.001 | 000 |
CPT_IP | -- | 0.220* | 0.28 | 0.22 | 0.044 | 0.06 | 0.60 | 0.303*** | 0.70 | −0.01 | 0.000 | 0.00 |
CVLT 1–5 | -- | 0.189 | 0.23 | 0.26 | 0.061 | 0.08 | 0.48 | 0.193** | 0.34 | 0.16 | 0.021 | 0.04 |
Medium and large effect sizes (f2) are bolded. Positive β at step 2 indicate larger volume is associated with better cognitive performance, at step 3 indicates better cognitive performance in the control group than in the 22q11DS patient group.
p < 0.05
p<0.01
p<0.001